Abstract:Therapeutic recombinant proteins have numerous advantages and benefits over chemical drugs, particularly high specificity and good biocompatibility. However, the therapeutic potential and clinical application of current anticancer protein drugs are limited as most biomarkers are located within cells, and multiple physiological barriers exist between the point of administration and the intracellular biomarker. Herein, we report a novel strategy to accurately deliver a cell-permeable dominant-negative TATm-Survivin (TmSm) protein (T34A) to intracellular survivin in cancer cells by overcoming multiple barriers in vivo. A poly(d,l-lactide-co-glycolide) (PLGA) inner core, a polyethylene glycol (PEG) modification, and a TATm peptide were simultaneously introduced to mediate tumor tissue targeting and response to pH-triggered TmSm release. Compared to free TmSm, the PEGylated-PLGA nanoparticle platform achieved a significantly higher cellular uptake efficiency (1.79-fold for A549 and 1.77-fold for Capan-2), effectively decreased IC50 (1.22-fold for A549 and 1.17-fold for Capan-2), and largely elevated apoptosis in different cancer cells (1.17-fold for A549 and 1.15-fold for Capan-2). Besides, this newly developed nanoplatform showed increased protein drug accumulation in the tumor site in A549-bearing nude mice and reached a tumor inhibition rate of 55.81% (1.35-fold versus free TmSm) by reducing the expression of intracellular survivin. All these results confirmed that our newly developed delivery strategy is a very promising tool, which helps protein drugs to cross multiple barriers in vivo and achieves precise targeting to intracellular biomarkers. This strategy could also be applied to other types of protein drugs to further improve their clinical anticancer therapeutic efficacy.

Survivin Promoter and Tumor

Survioin promoter activity in tumor cell lines

Cancer-specific activation of the survivin promoter and its potential use in gene therapy

Expression and Clinical Significance of Survivin in Transitional Cell Carcinoma of Bladder

Preliminary Study of Cell Cycle Specific Survivin Promotor Activity in Glioblastoma Cell Line

Tumor-specific transcriptional targeting of suicide gene therapy

Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters

Suppressor of Ty homolog-5, a novel tumor-specific human telomerase reverse transcriptase promoter-binding protein and activator in colon cancer cells

A Study on the Activity of Htert Promoter Related Tumor Targeting Gene on Colon Cancer Cell Line DLD-1

The Research Progress of Survivin Promoting Tumor Genesis and Development

Sp1 and Sp3 Regulate Basal Transcription of the Survivin Gene

Survivin as a Therapeutic Target for the Treatment of Human Cancer

Survivin And Tumorigenesis: Molecular Mechanisms And Therapeutic Strategies

Induced Epigenetic Modifications of the Promoter Chromatin Silence Survivin and Inhibit Tumor Growth.

Cloning of survivin promoter and its specific transcriptional activities in gastric cancer cell line AGS

Effect of Survivin-antisense on Liver Cancer Cell Line SMMC-7721 in Inducing Apoptosis and Increasing Its Sensitivity to Antineoplastic Agents

Targeted Treatment of Hepatoma Using HSV-TK Suicide Gene with the PBI-SUR-TK Vector

MicroRNA Regulation and Therapeutic Targeting of Survivin in Cancer.

Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy

Multiple targeting strategies achieve novel protein drug delivery into proapoptosis lung cancer cells by precisely inhibiting survivin

Multi-omic analysis suggests tumor suppressor genes evolved specific promoter features to optimize cancer resistance